Head-to-head · WeighScore
Henry Meds vs Oak
The verdict
Henry Meds takes it — 77.3/100 to 63.2/100.
Henry Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A flat-fee compounded pioneer — simple, but priced at the higher end of the ranking now.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Henry Meds | Oak |
|---|---|---|
| WeighScore | 77.3/100 | 63.2/100 |
| Grade | C+ | C |
| Scorecard rank | #50 | #217 |
| Semaglutide | $249/mo | $250/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $200/mo that morning |
| Tirzepatide | $349/mo | $300/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $250/mo that morning |
| Coverage | Multi-state | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #50 · C+
Strengths
- Simple flat-fee model
- Established brand
- Both molecules
Where it loses points
- Higher pricing than newer entrants
- Compounded only
Graded #217 · C
Strengths
- No membership or subscription fee, and free shipping
- All 50 states, offered in Spanish as well as English
- One price at every dose, so titrating up does not cost more — its order form states it as "One price · All dosages" beside the figure itself
- The price is reachable without handing over any medical detail: the figures sit on the first screen of its order form, before a single question is answered
Where it loses points
- Its advertising and its order form disagree: none of the nine "starting" figures it markets is the $200/$250 it actually charges, so anyone comparing on the advertised numbers is comparing against a price Oak does not offer
- Nine conflicting "starting" figures appear across Oak's own pages — $119, $133, $160, $167, $180, $185, $190, $199 and $250 — and none carries a term or a billing cadence. Its headline "$133 / $199" is the three-month prepay under code OAKSAVE200, billed upfront, not a monthly rate
- The cheapest two, "$119" and "$185", sit beside a "$200 off" new-patient offer that Oak elsewhere describes as "$50 off your first month, $200 off 3-months" — a three-month package discount, not a monthly rate
- Its two comparison tables disagree with each other and with its two FAQs: $167/mo against $190/mo, "as little as $119/month" against "as little as $190/month or lower"
- Worth re-checking at the last step: an earlier reading of its checkout copy recorded dose steps costing roughly $50–$75 more, which its order form's "One price · All dosages" line contradicts
- Same-day approval with no video call means very little clinical contact before a prescription
- No published lab or monitoring program
- Injection only, and no brand-name lane
- Sold as packages, so re-ordering is on you
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 544 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.